LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | SU11274 | 3.33 | uM | LJP5 | 2 | J08 | 72 | hr | 1401 | 3775 | 4223 | 0.8939 | 0.8412 |
| SK-BR-3 | SU11274 | 3.33 | uM | LJP5 | 3 | J08 | 72 | hr | 1401 | 4420 | 4223 | 1.0466 | 1.0698 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 1 | L02 | 72 | hr | 1401 | 2682 | 4223 | 0.6351 | 0.4538 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 2 | L02 | 72 | hr | 1401 | 2733 | 4223 | 0.6472 | 0.4719 |
| SK-BR-3 | Fedratinib | 3.33 | uM | LJP5 | 3 | L02 | 72 | hr | 1401 | 3180 | 4223 | 0.7530 | 0.6303 |
| SK-BR-3 | TGX221 | 3.33 | uM | LJP5 | 1 | H20 | 72 | hr | 1401 | 3979 | 4223 | 0.9422 | 0.9135 |
| SK-BR-3 | TGX221 | 3.33 | uM | LJP5 | 2 | H20 | 72 | hr | 1401 | 4030 | 4223 | 0.9543 | 0.9316 |
| SK-BR-3 | TGX221 | 3.33 | uM | LJP5 | 3 | H20 | 72 | hr | 1401 | 4622 | 4223 | 1.0945 | 1.1414 |
| SK-BR-3 | Torin1 | 3.33 | uM | LJP6 | 1 | O14 | 72 | hr | 1401 | 1411 | 4223 | 0.3341 | 0.0034 |
| SK-BR-3 | Torin1 | 3.33 | uM | LJP6 | 2 | O14 | 72 | hr | 1401 | 1305 | 4223 | 0.3090 | -0.0342 |
| SK-BR-3 | Torin1 | 3.33 | uM | LJP6 | 3 | O14 | 72 | hr | 1401 | 1485 | 4223 | 0.3516 | 0.0296 |
| SK-BR-3 | Torin2 | 3.33 | uM | LJP5 | 1 | I20 | 72 | hr | 1401 | 1020 | 4223 | 0.2415 | -0.1352 |
| SK-BR-3 | Torin2 | 3.33 | uM | LJP5 | 2 | I20 | 72 | hr | 1401 | 1102 | 4223 | 0.2610 | -0.1062 |
| SK-BR-3 | Torin2 | 3.33 | uM | LJP5 | 3 | I20 | 72 | hr | 1401 | 1070 | 4223 | 0.2534 | -0.1175 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 1 | B14 | 72 | hr | 1401 | 1420 | 4223 | 0.3363 | 0.0065 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 2 | B14 | 72 | hr | 1401 | 1463 | 4223 | 0.3464 | 0.0218 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 3 | B14 | 72 | hr | 1401 | 1403 | 4223 | 0.3322 | 0.0005 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 1 | P20 | 72 | hr | 1401 | 3143 | 4223 | 0.7442 | 0.6172 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 2 | P20 | 72 | hr | 1401 | 3395 | 4223 | 0.8039 | 0.7065 |
| SK-BR-3 | Trametinib | 3.33 | uM | LJP5 | 3 | P20 | 72 | hr | 1401 | 3924 | 4223 | 0.9292 | 0.8940 |
| SK-BR-3 | TWS119 | 3.33 | uM | LJP5 | 1 | M02 | 72 | hr | 1401 | 1740 | 4223 | 0.4120 | 0.1200 |
| SK-BR-3 | TWS119 | 3.33 | uM | LJP5 | 2 | M02 | 72 | hr | 1401 | 3792 | 4223 | 0.8979 | 0.8472 |
| SK-BR-3 | TWS119 | 3.33 | uM | LJP5 | 3 | M02 | 72 | hr | 1401 | 3555 | 4223 | 0.8418 | 0.7632 |
| SK-BR-3 | Vemurafenib | 3.33 | uM | LJP5 | 1 | C14 | 72 | hr | 1401 | 4046 | 4223 | 0.9581 | 0.9372 |
| SK-BR-3 | Vemurafenib | 3.33 | uM | LJP5 | 2 | C14 | 72 | hr | 1401 | 4302 | 4223 | 1.0187 | 1.0280 |